Logo image of VERU

VERU INC (VERU) Stock Fundamental Analysis

USA - NASDAQ:VERU - US92536C2026 - Common Stock

3.72 USD
-0.4 (-9.71%)
Last: 10/23/2025, 8:00:02 PM
3.76 USD
+0.04 (+1.08%)
After Hours: 10/23/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VERU. VERU was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of VERU is average, but there are quite some concerns on its profitability. VERU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERU has reported negative net income.
VERU had a negative operating cash flow in the past year.
In the past 5 years VERU reported 4 times negative net income.
In the past 5 years VERU always reported negative operating cash flow.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

VERU's Return On Assets of -96.59% is on the low side compared to the rest of the industry. VERU is outperformed by 76.44% of its industry peers.
With a Return On Equity value of -144.48%, VERU is not doing good in the industry: 67.54% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -96.59%
ROE -144.48%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

The Gross Margin of VERU (39.70%) is better than 61.26% of its industry peers.
In the last couple of years the Gross Margin of VERU has declined.
VERU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERU has been increased compared to 1 year ago.
The number of shares outstanding for VERU has been increased compared to 5 years ago.
The debt/assets ratio for VERU has been reduced compared to a year ago.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

VERU has an Altman-Z score of -10.49. This is a bad value and indicates that VERU is not financially healthy and even has some risk of bankruptcy.
VERU has a worse Altman-Z score (-10.49) than 70.16% of its industry peers.
There is no outstanding debt for VERU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.49
ROIC/WACCN/A
WACC8.79%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

VERU has a Current Ratio of 4.47. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
VERU has a Current ratio of 4.47. This is in the better half of the industry: VERU outperforms 65.97% of its industry peers.
VERU has a Quick Ratio of 4.47. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.47, VERU is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

VERU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -126.80%.
The Revenue has been growing slightly by 3.62% in the past year.
Measured over the past years, VERU shows a very negative growth in Revenue. The Revenue has been decreasing by -11.89% on average per year.
EPS 1Y (TTM)-126.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 21.75% on average over the next years. This is a very strong growth
Based on estimates for the next years, VERU will show a very strong growth in Revenue. The Revenue will grow by 57.70% on average per year.
EPS Next Y-4.58%
EPS Next 2Y-13.07%
EPS Next 3Y-15.23%
EPS Next 5Y21.75%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y57.7%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 2029 2030 2031 100M 200M 300M 400M 500M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VERU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VERU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A cheap valuation may be justified as VERU's earnings are expected to decrease with -15.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.07%
EPS Next 3Y-15.23%

More info and screens

0

5. Dividend

5.1 Amount

VERU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERU INC

NASDAQ:VERU (10/23/2025, 8:00:02 PM)

After market: 3.76 +0.04 (+1.08%)

3.72

-0.4 (-9.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)12-15 2025-12-15/amc
Inst Owners26.46%
Inst Owner Change-0.82%
Ins Owners10.7%
Ins Owner Change0%
Market Cap54.54M
Revenue(TTM)16.89M
Net Income(TTM)-38471000
Analysts82
Price Target21.68 (482.8%)
Short Float %7.34%
Short Ratio1.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.55%
Min EPS beat(2)20.51%
Max EPS beat(2)22.6%
EPS beat(4)2
Avg EPS beat(4)-0.97%
Min EPS beat(4)-28.68%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)8.3%
EPS beat(12)5
Avg EPS beat(12)-8.84%
EPS beat(16)8
Avg EPS beat(16)1.35%
Revenue beat(2)1
Avg Revenue beat(2)-8.34%
Min Revenue beat(2)-100%
Max Revenue beat(2)83.32%
Revenue beat(4)3
Avg Revenue beat(4)7.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)83.32%
Revenue beat(8)4
Avg Revenue beat(8)-4.34%
Revenue beat(12)5
Avg Revenue beat(12)-17.01%
Revenue beat(16)7
Avg Revenue beat(16)-12.43%
PT rev (1m)0%
PT rev (3m)672.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-900%
EPS NY rev (1m)4.7%
EPS NY rev (3m)-761.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.7
P/FCF N/A
P/OCF N/A
P/B 2.05
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)-2.2
EYN/A
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS1.01
BVpS1.82
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.59%
ROE -144.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.7%
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.05%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z -10.49
F-Score4
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-126.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y-4.58%
EPS Next 2Y-13.07%
EPS Next 3Y-15.23%
EPS Next 5Y21.75%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y57.7%
EBIT growth 1Y42.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y63.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.21%
OCF growth 3YN/A
OCF growth 5YN/A